This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 High Earnings Yield Picks That Command Your Attention
by Rimmi Singhi
Level up your portfolio with high earnings yield stocks including ArcelorMittal (MT), Moderna, (MRNA), Shell (RDS.A), Magna (MGA), Winnebago (WGO).
Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails
by Zacks Equity Research
Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.
Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply
by Zacks Equity Research
Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.
Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
Top Stock Picks for Week of March 1, 2021
by Panel Of Zacks Experts
A Leader in Covid-19 Vaccine and a Company Showing Positivity.
Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit
by Zacks Equity Research
Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion. Stock up.
FDA Emergency Nod for J&J COVID-19 Vaccine Heats Up Competition
by Kinjel Shah
J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.
Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall
by Zacks Equity Research
Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.
BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.
Nasdaq ETF's Worst Day Since October: Stocks That Survived
by Sanghamitra Saha
The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.
Jobless Claims, Q4 GDP Dip; Durable Goods Soar +3.4%
by Mark Vickery
While jobless claims fell on weather-related issues, Durable Goods were up big for January.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Moderna (MRNA) Misses on Q4 Earnings, Eyes $18B in Vaccine Sales
by Zacks Equity Research
Moderna (MRNA) records product sales for the first time which comprises sales of its coronavirus vaccine, mRNA-1273. Stock up.
Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of -176.00% and 74.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Q4 Earnings & Sales Top, 2021 Outlook Bright
by Zacks Equity Research
Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations. Stock up.
Markets Break Higher; NVIDIA Beats Q4 Expectations
by Mark Vickery
NVIDIA (NVDA) beat estimates on both top and bottom lines after regular trading this afternoon.
Is a Surprise Coming for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arena (ARNA) Q4 Earnings Miss Estimates, Pipeline Progresses
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson
5 Pandemic Winner Earnings Charts
by Tracey Ryniec
These 5 companies were beneficiaries of the pandemic economy. But what happens next?
Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.
FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs
by Kinjel Shah
The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.